Cullinan Therapeutics, Inc. - COMMON STOCK (CGEM)

CUSIP: 230031106

Q3 2025 13F Holders as of 30 Sep 2025

Holder snapshot 7 signals
Share change
-1,416,014
Put/Call ratio
135%
SEC-reported price per share
$5.93
Indexed holders
142
Value change
-$12,503,675
Number of buys
82
Open additional details 1 more signal available
Number of sells
62
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
65,102,625

Security key

230031106

Report period

Q3 2025

Indexed institutions

142

Top holders

10

Ownership snapshot

Top reported holders of CGEM - Cullinan Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
James E. Flynn
Disclosed value leader
Ansbert Gadicke
Comparable rows
3/15
Latest evidence
30 Sep 2025
13D/G 13F 3/4/5 Lead comparable stake: 5% 12 rows are not safely comparable across share classes. 13D/G row: James E. Flynn Showing 1-6 of 15 holder rows.

Quick read

James E. Flynn leads the comparable SEC ownership view at 5%.

3 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens James E. Flynn's linked filing trail.
Comparable ownership Top 3
James E. Flynn 5%
FRANKLIN TEMPLETON INC 3.8%
CITADEL ADVISORS LLC 3.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
James E. Flynn
13D/G
Deerfield Mgmt, L.P.
5%
Reported 13D/G · 30 Sep 2025
$17,357,187
2,927,013 shares
$0 30 Sep 2025
FRANKLIN TEMPLETON INC
13D/G 13F
Franklin Resources, Inc. · Company
3.8%
Reported 13D/G · 30 Sep 2024
$17,836,873
2,191,262 shares
$0 30 Sep 2024
CITADEL ADVISORS LLC
13F 13D/G
Company · Kenneth Griffin
3.4%
Reported 13D/G · 30 Sep 2025
$19,681,108
2,613,693 shares
— 30 Jun 2025
UBS Oncology Impact Fund L.P.
3/4/5
10%+ Owner
—
denominator unverified
$95,297,419
7,648,268 shares
— 16 Sep 2021
Morana Jovan-Embiricos
3/4/5
10%+ Owner
—
denominator unverified
$56,397,201
4,526,260 shares
— 24 Jun 2022
Vision Scs F2
3/4/5
10%+ Owner
—
denominator unverified
$55,775,322
4,476,350 shares
— 02 Aug 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
142
Shares
61,075,479
Indexed holders
142
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 indexed holders
141
Q3 2025 indexed holders
142
Indexed holder difference
1
Investor Q2 2025 Shares Q3 2025 Shares Share Diff Share Chg % Q2 2025 value Q3 2025 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .